These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 32663198)

  • 1. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
    Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
    J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression.
    Chen F; Sheng J; Li X; Gao Z; Hu L; Chen M; Fei J; Song Z
    Front Immunol; 2024; 15():1451474. PubMed ID: 39290697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
    Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
    Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy.
    Gondaliya P; Sayyed AA; Yan IK; Driscoll J; Ziemer A; Patel T
    Mol Ther; 2024 Aug; 32(8):2762-2777. PubMed ID: 38859589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments.
    Jachetti E; Sangaletti S; Chiodoni C; Ferrara R; Colombo MP
    Cell Immunol; 2021 Apr; 362():104301. PubMed ID: 33588246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting myeloid-derived suppressor cells promotes antiparasitic T-cell immunity and enhances the efficacy of PD-1 blockade (15 words).
    Zhang C; Wang H; Aji T; Li Z; Li Y; Ainiwaer A; Rousu Z; Li J; Wang M; Deng B; Duolikun A; Kang X; Zheng X; Yu Q; Shao Y; Zhang W; Vuitton DA; Tian Z; Sun H; Wen H
    Nat Commun; 2024 Jul; 15(1):6345. PubMed ID: 39068159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.
    Lomphithak T; Akara-Amornthum P; Murakami K; Hashimoto M; Usubuchi H; Iwabuchi E; Unno M; Cai Z; Sasano H; Jitkaew S
    Sci Rep; 2021 Jun; 11(1):11743. PubMed ID: 34083572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
    Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
    Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
    Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
    J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
    Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer.
    Xin G; Chen Y; Topchyan P; Kasmani MY; Burns R; Volberding PJ; Wu X; Cohn A; Chen Y; Lin CW; Ho PC; Silverstein R; Dwinell MB; Cui W
    Cancer Immunol Res; 2021 Apr; 9(4):454-469. PubMed ID: 33579728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocytic myeloid-derived suppressor cells inhibit T follicular helper cells during experimental Schistosoma japonicum infection.
    Zhang Y; Wu Y; Liu H; Gong W; Hu Y; Shen Y; Cao J
    Parasit Vectors; 2021 Sep; 14(1):497. PubMed ID: 34565440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles.
    Bayik D; Lauko AJ; Roversi GA; Serbinowski E; Acevedo-Moreno LA; Lanigan C; Orujov M; Lo A; Alban TJ; Kim A; Silver DJ; Nagy LE; Brown JM; Allende DS; Aucejo FN; Lathia JD
    Sci Rep; 2020 Nov; 10(1):18848. PubMed ID: 33139767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
    Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.